Morgan Stanley Portfolio holdings
Morgan Stanley, founded in 1935 by Henry Sturgis Morgan and Harold Stanley as a spin-off from J.P. Morgan & Co., is a leading global financial services firm headquartered in New York City. Initially focused on investment banking, it has evolved into a diversified powerhouse offering wealth management, institutional securities, and asset management services, catering to corporations, governments, institutions, and high-net-worth individuals. With a strong presence in mergers and acquisitions, underwriting, and trading, Morgan Stanley manages billions in assets and is known for its sophisticated financial advisory services. The firm has adapted to modern markets by expanding its digital offerings and wealth management division, notably through its 2020 acquisition of E*TRADE, solidifying its position as a Wall Street titan.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$836M |
| 2 |
Microsoft
MSFT
|
+$748M |
| 3 |
Cigna
CI
|
+$560M |
| 4 |
3M
MMM
|
+$558M |
| 5 |
JPMorgan Ultra-Short Income ETF
JPST
|
+$535M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$568M |
| 2 |
Zoom
ZM
|
+$557M |
| 3 |
State Street Utilities Select Sector SPDR ETF
XLU
|
+$516M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$479M |
| 5 |
Unity
U
|
+$476M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.72% |
| 2 | Healthcare | 11.35% |
| 3 | Financials | 9.44% |
| 4 | Consumer Discretionary | 8.31% |
| 5 | Communication Services | 5.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
5601
Immuneering
IMRX
$331M
| $168K | ﹤0.01% |
11,749
-6,538
| -36% | -$51.9K |
|
|
MMAT
5602
DELISTED
Meta Materials Inc. Common Stock
MMAT
| $168K | ﹤0.01% |
2,593
-26,036
| -91% | -$2.28M |
|
5603
Curis
CRIS
$3.97M
| $167K | ﹤0.01% |
596
+218
| +58% | +$87.9K |
|
5604
Sol-Gel Technologies
SLGL
$278M
| $167K | ﹤0.01% |
3,344
-350
| -9% | -$19.4K |
|
5605
Verastem
VSTM
$597M
| $167K | ﹤0.01% |
16,338
-8,340
| -34% | -$116K |
|
5606
CapForce IBD 50 ETF
FFTY
$81.1M
| $166K | ﹤0.01% |
6,816
+804
| +13% | +$22.3K |
|
5607
Pro-Dex
PDEX
$216M
| $166K | ﹤0.01% |
9,351
+301
| +3% | +$5.17K |
|
5608
Invesco S&P 500 Momentum ETF
SPMO
$22.3B
| $166K | ﹤0.01% |
3,300
-400
| -11% | -$21.7K |
|
5609
Entrada Therapeutics
TRDA
$285M
| $166K | ﹤0.01% |
10,530
-10,655
| -50% | -$135K |
|
5610
Innovator Growth-100 Power Buffer ETF October
NOCT
$230M
| $165K | ﹤0.01% |
4,755
+755
| +19% | +$27.9K |
|
|
DTF
5611
DTF Tax-Free Income 2028 Term Fund
DTF
$80.9M
| $164K | ﹤0.01% |
14,799
+226
| +2% | +$2.7K |
|
5612
HF Foods Group
HFFG
$99.2M
| $164K | ﹤0.01% |
42,592
-74,262
| -64% | -$368K |
|
5613
Magyar Bancorp
MGYR
$125M
| $164K | ﹤0.01% |
13,192
-1,500
| -10% | -$18.4K |
|
|
MTLS
5614
Materialise
MTLS
$398M
| $163K | ﹤0.01% |
15,215
-3,080
| -17% | -$39.2K |
|
5615
a.k.a. Brands
AKA
$115M
| $162K | ﹤0.01% |
9,321
-3,130
| -25% | -$80.5K |
|
|
BCLI
5616
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
| $162K | ﹤0.01% |
2,434
-298
| -11% | -$14.9K |
|
|
TBHC
5617
DELISTED
The Brand House Collective
TBHC
| $162K | ﹤0.01% |
53,820
-51,546
| -49% | -$198K |
|
5618
Schwab 5-10 Year Corporate Bond ETF
SCHI
$11.5B
| $162K | ﹤0.01% |
7,720
+3,830
| +98% | +$85.4K |
|
5619
Inspire Global Hope ETF
BLES
$165M
| $161K | ﹤0.01% |
5,800
-550
| -9% | -$17K |
|
5620
Avita Medical
RCEL
$246M
| $161K | ﹤0.01% |
30,449
-37,077
| -55% | -$229K |
|
|
CORZ
5621
DELISTED
Core Scientific, Inc. Common Stock
CORZ
| $161K | ﹤0.01% |
124,213
-183,917
| -60% | -$391K |
|
5622
Bit Digital
BTBT
$537M
| $160K | ﹤0.01% |
132,896
-750,693
| -85% | -$1.15M |
|
5623
FlexShares US Quality Low Volatility Index Fund
QLV
$168M
| $160K | ﹤0.01% |
3,445
-2,248
| -39% | -$113K |
|
|
HTY
5624
DELISTED
JOHN HANCOCK TAX-ADVANTAGED GLOBAL SHAREHOLDER YIELD FUND
HTY
| $160K | ﹤0.01% |
36,055
+4,549
| +14% | +$23.8K |
|
5625
Inspire Small/Mid Cap Impact ETF
ISMD
$347M
| $159K | ﹤0.01% |
5,800
-1,358
| -19% | -$41.2K |
|
Similar funds
Morgan Stanley's Q3 2022 Portfolio in Review
As of Q3 2022, Morgan Stanley held 8,241 positions worth $734B, down 4.8% from $770B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Morgan Stanley's Q3 2022 filing shows 197 new, 3,111 increased, 3,746 reduced and 238 closed positions. Its largest new stake was Mondee Holdings, Inc. Class A Common Stock: 9,699,165 shares worth $75.8M. The largest sale was Amgen, an estimated $568M.
By sector, the portfolio is most concentrated in Technology at 18% of assets, down from 18% a quarter earlier, followed by Healthcare and Financials.
- Morgan Stanley's largest Q3 2022 buy was Mondee Holdings, Inc. Class A Common Stock: 9,699,165 shares worth $75.8M.
- Morgan Stanley added most to State Street SPDR S&P 500 ETF Trust in Q3 2022, an estimated $836M increase.
- Morgan Stanley's biggest Q3 2022 reduction was Amgen, cutting an estimated $568M.
- Morgan Stanley fully exited Coherent Inc in Q3 2022, selling an estimated $104M.
- Morgan Stanley's ten largest holdings make up 16% of its $734B portfolio in Q3 2022.
- Morgan Stanley opened 197 new positions and closed 238 in Q3 2022.
- Morgan Stanley's portfolio value fell 4.8% quarter-over-quarter to $734B.
Based on Morgan Stanley's 13F filing for Q3 2022, filed 14 Nov 2022.